Yahoo Finance • 6 days ago
(RTTNews) - Cidara Therapeutics, Inc. (CDTX), a biotechnology company, on Friday announced that the first participants have been dosed in its Phase 3 trial to evaluate the safety and efficacy of its drug candidate CD388 in populations at h... Full story
Yahoo Finance • 7 days ago
- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN... Full story
Yahoo Finance • 8 days ago
[$100 Growth Rolling Banknote, Green Arrow, Object + Shadow Clipping Path] Cidara Therapeutics (NASDAQ:CDTX [https://seekingalpha.com/symbol/CDTX]) added ~15% on Wednesday after the biotech announced an accelerated timeline for a Phase 3... Full story
Yahoo Finance • 8 days ago
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA a... Full story
Yahoo Finance • 9 days ago
In recent trading, shares of Cidara Therapeutics Inc (Symbol: CDTX) have crossed above the average analyst 12-month target price of $74.00, changing hands for $75.47/share. When a stock reaches the target an analyst has set, the analyst l... Full story
Yahoo Finance • 28 days ago
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company mana... Full story
Yahoo Finance • 2 months ago
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vertiv Holdings Co (Symbol: VRT), where a total of 65,043 contracts have traded so far, representing approximately 6.5 million und... Full story
Yahoo Finance • 2 months ago
Investing.com - Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $70.00 from $69.00 on Friday, while maintaining a Buy rating following the company’s second-quarter 2025 earnings release. The $1.37 billion m... Full story
Yahoo Finance • 2 months ago
Investing.com - Citizens JMP has raised its price target on Cidara Therapeutics (NASDAQ:CDTX) to $66.00 from $59.00, while maintaining a Market Outperform rating. The company, currently valued at $1.37 billion, has seen its stock surge ove... Full story
Yahoo Finance • 2 months ago
Investing.com - RBC Capital raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $115.00 from $75.00 on Wednesday, while maintaining an Outperform rating. The biotech company, now valued at $1.35 billion, has delivered rem... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compen... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to... Full story
Yahoo Finance • 3 months ago
LONDON - Contract research organization hVIVO PLC (AIM:HVO) announced Monday that its client Cidara Therapeutics (NASDAQ:CDTX) has achieved positive topline results in a Phase 2b field study for CD388, a drug designed to prevent seasonal i... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the clos... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the clo... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pric... Full story
Yahoo Finance • 3 months ago
Investing.com - RBC Capital raised its price target on Cidara Therapeutics (NASDAQ:CDTX) to $75.00 from $35.00 on Tuesday, while maintaining an Outperform rating on the stock. The price target increase follows what RBC described as "best-... Full story
Yahoo Finance • 3 months ago
Investing.com - Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) to $68.00 from $50.00 on Tuesday, maintaining a Buy rating following impressive Phase 2b trial results for the company’s flu prevention treatment. For... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its pla... Full story
Yahoo Finance • 6 months ago
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced th... Full story